Abstract
We evaluated the incidence of three types of tardive dyskinesia (withdrawal, persistent, and masked) in the context of clinically determined changes in neuroleptic medication status in persons with developmental disabilities. We investigated 56 subjects residing at a public residential facility. Based on changes in neuroleptic dosage over a ten-month period, four groups were formed: (1) significantly decreased dose, (2) slightly decreased dose, (3) no change, and (4) increased dose. Withdrawal TD was observed in about 60% of the subjects in the group defined by a significant decrease in dose. Persistent TD was observed in approximately 50% of the subjects in the two groups defined by little or no change in medication (slight decrease and no change in dose). Masked TD was observed in 60% of the subjects in the group defined by an increase in dose. Categorizing TD in this fashion may aid in its early diagnosis and subsequent treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aman, M. G. (1983). Psychoactive drugs in mental retardation. In Matson, J. L., and Andrasik, F. (eds.),Treatment Issues and Innovations in Mental Retardation, Plenum Press, New York, pp. 455–513.
Aman, M. G., and Singh, N. N. (1980). The usefulness of thioridazine for treating childhood disorders—Fact or fokelore?Am. J. Ment. Def. 84: 331–338.
Aman, M. G., and Singh, N. N. (1988).Psychopharmacology of the Developmentally Disabled, Springer-Verlag, New York.
American Psychiatric Association. (1979).Task Force Report 18: Tardive Dyskinesia, American Psychiatric Association, Washington, DC.
Berkson, G., and Davenport, R. K. (1962). Stereotyped movements of mental defectives.Am. J. Ment. Def. 66: 849–852.
Briggs, R., Gerrard, S., Hamad, C., and Willis, F. (1984). A model for evaluating psychoactive medication use with mentally retarded persons. In Mulick, J. A., and Mallory, B. L.,Transitions in Mental Retardation (Vol. 1):Advocacy, Technology, and Sciences, Ablex, Norwood, New Jersey, pp. 229–248.
Fielding, L. T., Murphy, R. J., Regan, M. W., and Peterson, T. L. (1980). An assessment program to reduce drug use with mentally retarded.Hosp. Commun. Psychiatry 31: 771–773.
Gadow, K. D., and Poling, A. G. (1988).Pharmacotherapy and Mental Retardation, College Hill Publications, San Diego.
Granger, D. A., Yurkunski, J. M., Miller, N. H., Swanson, J. M., and Crinella, F. M. (1987). Systematic dyskinesia examination of the profoundly retarded: Cooperation and assessment.Am. J. Psychiatry 141: 20–23.
Gualtieri, C. T., Quade, D., Hicks, R. E., Mayo, J. P., and Schroeder, S. R. (1984). Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents.Am. J. Psychiatry 141: 20–23.
Guy, W. (Ed.) (1976).ECDEU Assessment Manual for Psychopharmacology, U.S. Government Printing Office, Washington D.C.
Inoue, F. (1982). A clinical pharmacy service to reduce psychotropic medication use in an institution for mentally handicapped person.Ment. Retard. 19: 16–19.
Jeste, D. V., and Wyatt, R. J. (1982).Understanding and Treating Tardive Dyskinesia, Guildford, New York.
Kalachnik, J. E. (1988). Medication monitoring procedures: Thou shall, here's how. In Gadow, K. D., and Poling, A. G. (eds.),Pharmacotherapy and Mental Retardation, College Hill Publication, San Diego.
Kalachnik, J. E., and Harder, S. R., Kidd-Nielsen, N. P., Errickson, E., Doebler, M., and Sprague, R. L. (1984). Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no neuroleptic history groups: Preliminary results.Psychopharmacol. Bull. 20: 27–32.
Kalachnik, J. E., Kidd-Nielsen, N. P., and Harder, S. R. (1983). Nature of nonassessable items and cooperative level of the retarded during systematic dyskinesia examination.Psychopharmacol. Bull. 19: 16–19.
Kane, J. M., Woerner, M., Boerenstein, M., Wegner, J., and Liebermann, J. (1986). Integrating incidence and prevalence of tardive dyskinesia.Psychopharmacol. Bull. 22: 254–259.
Kastrup, E. K., and Olan, B. R. (1988).Drug Facts and Comparison, Lippincott, New York.
Kazamatsuri, H., Chien, C., and Cole, J. O. (1972). Treatment of tardive dyskinesia II: Short-term efficacy of dopamine-blocking agents, haloperidol, and thiopropazate.Arch. Gen. Psychiatry 27: 100–103.
Khot, V., and Wyatt, R. J. (1991). Not all that moves is tardive dyskinesia.Am. J. Psychiatry 87: 386–395.
LeMendola, W., Zaharia, E. S., and Carver, M. (1980). Reducing psychotropic drug use in an institution for the retarded.Hosp. Commun. Psychiatry 31: 271–272.
Morgenstein, H., Glazer, W. M., Niedzwiecki, and Nourjah, P. (1987). The impact of neuroleptic medication on tardive dyskinesia: A meta-analysis of published studies.Am. J. Psychiatric Hosp. 77: 717–724.
Richardson, M. A., Haugland, G., Pass, R., and Craig, T. J. (1986). The prevalence of tardive dyskinesia in a mentally retarded population.Psychopharmacol. Bull. 22: 243–249.
Rinck, C., Guidry, J., and Calkins, C. F. (1989). Review of States' practices on the use of psychotropic medication.Am. J. Ment. Retard. 93: 657–668.
Schooler, N., and Kane, J. (1982). Research diagnoses for tardive dyskinesia.Arch. Gen. Psychiatry 39: 486–487.
Seeman, P. (1980). Brain dopamine receptors.Pharmacol. Rev. 32: 229–313.
Simpson, G. M., Lee, J. H., Zuobok, B., and Gardos (1979). A rating scale for tardive dyskinesia.Psychopharmacology 64: 171–179.
Simpson, G. M., Pi, E. H., and Sramek, J. J. (1986). An update on tardive dyskinesia.Hosp. Commun. Psychiatry 37: 362–368.
Singh, N. N., and Aman, M. G. (1981). Effects of thioridazine dosage on the behavior of severely retarded persons.Am. J. Ment. Def. 85: 580–587.
Smith, R. C. (1980). Smith Tardive Dyskinesia Scale. In Fann, W. E., Smith, R. C., Davis, J. M., and Domino, E. F. (eds.),Tardive Dyskinesia and Treatment, Spectrum Publications, Jamaica, NY.
Sprague, R. L. (1982a). An analysis of institutionalized retarded residents using Dis-Co.Psychopharmacol. Bull. 18: 60–61.
Sprague, R. L. (1982b). Litigation, laws, and regulations regrading psychoactive drug use. In Breuning, S. E., and Poling, A. D. (eds.),Drugs and Mental Retardation, Charles C. Thomas, Springfield, IL, pp. 377–414.
Sprague, R. L., and Baxley, G. B. (1978). Drugs for behavior management, with comment on some legal aspects. In Wortis, J. (ed.),Mental Retardation (Vol. 10), Brunner/Mazel, New York, pp. 92–129.
Sprague, R. L., and Newell, K. M. (1987). Toward a movement control perspective of tardive dyskinesia. In Meltzer, H. Y. (ed.),Psychopharmacology: The Third Generation of Progress, Raven Press, New York, pp. 1233–1238.
Sprague, R. L., and Werry, J. S. (1971). Methodology of psychopharmacological studies with the retarded.Int. Rev. Res. Ment. Retard. 5: 147–219.
Sprague, R. L., White, D. M., Ullman, R., and Kalachnik, J. E. (1984). Methods for selecting items in a tardive dyskinesia rating scale.Psychopharmacol. Bull. 20: 339–345.
Wigal, T., Wigal, S., Fulbright, K. K., Swanson, J., Crinella, F., Ackerland, V., and Dean, D. (1992).Standardized videotaped procedure for evaluating withdrawal-emergent tardive dyskinesia in a public residential facility. Submitted for publication.
Williams, D. E., Weir, H. F., Hargrave, R. L., Parker, C. M., and Marek, K. (1984). Effects of a facility-wide psychoactive drug evaluation/behavior management system. In Griffin, J. C., Stark, M. T., Williams, D. E., Altmeyer, B. K., and Griffin, H. K. (eds.),Advances in the Treatment of Self-Injurious Behavior, Vol. Service Counsel for Richmond State School, Richmond, TX, pp. 153–164.
Zimmerman, R. L., and Heistad, G. T. (1982). Studies of long term efficacy of antipsychotic drugs in controlling the behavior of institutionalized retardates.J. Am. Acad. Child Psychiatry 21: 136–143.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wigal, T., Christian, D.L., Wigal, S.B. et al. Classification of types of tardive dyskinesia in a developmentally disabled population at a public residential facility. J Dev Phys Disabil 5, 55–69 (1993). https://doi.org/10.1007/BF01046598
Issue Date:
DOI: https://doi.org/10.1007/BF01046598